drugset / Trial / NCT03962049
Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The primary objective of this study is to assess the pharmacokinetics (PK) of linzagolix in subjects with varying degrees of impaired hepatic function compared to match control subjects with normal hepatic function
Timeline
- Start
- 2019-05-15
- Primary completion
- 2019-10-23
- Completion
- 2019-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | linzagolix | Unknown | 200 mg | Oral |
Indications
No indication recorded.